Skip to main content
. 2016 Oct 17;10(1):168–194. doi: 10.1177/1756283X16667909

Table 13.

Studies using CD40 agonist antibody.

Intervention Strategy Patient population Phase Year Results ClinicalTrials.gov identifier
CP-870,893 + Gemcitabine. Monoclonal antibody and cytotoxic drugs Pancreatic neoplasms I 2013 Overall survival 8.4 months Progression-free survival 5.3 months NCT00711191
CP-870,893 + Gemcitabine Monoclonal antibody and cytotoxic drugs PDAC I 2014 Pending NCT01456585
CP-870,893 Monoclonal antibody Advanced solid tumors I 2014 Pending NCT02225002